Haematologist | Developed the first CAR-T therapy for Myelofibrosis | @uclcancer Roddie/Pule lab #CART #MPN 🇬🇷🇬🇧 |Support by @BloodCancer_Res & @the_MRC
UCL Cancer Institute, UK
Joined August 2018
- Tweets3.3K
- Following1.5K
- Followers1.9K
- Likes9.2K
Pinned Tweet
1/ 🧵 So delighted to share our new paper, out today in Science Translational Medicine @ScienceTM. We built a CAR-T cell therapy that selectively depletes the disease-driving mutant calreticulin (mutCALR) cells in myelofibrosis — while sparing healthy blood stem cells👇
science.org/doi/10.1126/scit…
Alex Rampotas retweeted
Pleased to share our experience with outpatient/at-home CAR-T in Barcelona. 🧬🏠
Thanks to @EHA_Hematology for the invitation and for the opportunity to discuss our journey, challenges and lessons learned.
🎧 Listen to the podcast: ehaedu.org/outpatient-CAR…
@hospitalclinic
New podcast episode: Outpatient CAR T in Europe: Lessons from Barcelona
How can CAR T-cell therapy be safely delivered outside the hospital? Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz share their experience developing a fully outpatient CAR T programme in Barcelona, discussing patient selection, caregiver training, remote monitoring, safety, and lessons for centres looking to adopt similar approaches.
Listen the podcast: ehaedu.org/outpatient-CAR-T-…
Alex Rampotas retweeted
A good PI doesn’t just invest in research materials. They invest in YOU. @TheElfLab
Alex Rampotas retweeted
Exciting to see the anito-cel data finally published in @nejm
n = 38
100% triple class refractory myeloma. 68% penta-drug exposed. Med 4 prior lines
ORR 100% CRR 79%
2yr PFS 58%, median 30.2 mo
Only 3% (1 pt) grade 3 ICANS
No NINTS to date
Exciting!
nejm.org/doi/full/10.1056/NE…
Alex Rampotas retweeted
CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukemia | Leukemia share.google/aXjAlSxh0lUplye…
Alex Rampotas retweeted
ʙɪɴᴅᴄʀᴀꜰᴛ2 is out, and we're not waiting for the paper. The full code drops today, free for academic and industry use.
We're releasing it early so you can start designing right now, and bring its full power to the current Adaptyv competition.
github.com/PacesaLab/BindCra…
Alex Rampotas retweeted
Outcomes for post-transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study
British Journal of Haematology | Wiley Online Library share.google/mjWrHsr2jQH6MbV…
Very pleased to see this work coming out, bringing together one of the largest datasets of patients with relapsed B and T- ALL post transplant.
Many thanks to @drclaireroddie for the excellent supervision on this and @Capt__Kirkwood for the analysis and input
1/ What happens to adults with ALL who relapse after an allogeneic transplant, now that CAR-T, blinatumomab, inotuzumab and TKIs exist?
133 patients. 9 UK centres. 12 years.
New in @BrJHaem : onlinelibrary.wiley.com/doi/…
12/ Take-home: post-transplant ALL relapse is no longer uniformly fatal.
But the gains sit almost entirely in B-ALL, in low-burden relapse, and in patients who actually reach CAR-T therapy
T-ALL remains a genuine unmet need.
Alex Rampotas retweeted
👉👉👉Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic ... sciencedirect.com/science/ar… | led by @MKD_BMT @MediHumdani | | #BPDCN
@doctorpemm @hemant_murthy @DQBMD @lane_andy @BipinSavani
